ConductScience.org, home

Paper2015395

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.

Berman E and 9 others. Blood, 1991. Cited by 372 papers, by iCite.

Cite this record

ConductScience Library. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Papers, record 2015395. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2015395

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
PubMed
Journal
Blood
PubMed
Year
1991
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
372
iCite
Relative citation ratio, by iCite
10.8
iCite
Revised in PubMed
2022-04-08
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Berman EE
2Heller GG
3Santorsa JJ
4McKenzie SS
5Gee TT
6Kempin SS
7Gulati SS
8Andreeff MM
9Kolitz JJ
10Gabrilove JJ

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Leukemia, Myeloid, AcuteMajor topic
Adult
Analysis of Variance
Cytarabine
Daunorubicin
Female
Follow-Up Studies
Humans
Idarubicin
Leukocyte Count
Male
Probability

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01822015Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by73

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 372 citations.

PMIDTitleJournalYearIn PapersSource
41012572Daunomycin Nanocarriers with High Therapeutic Payload for the Treatment of Childhood Leukemia.Pharmaceutics2025https://conductscience.org/library/papers/41012572PubMed
40853377Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients.Ann Hematol2025https://conductscience.org/library/papers/40853377PubMed
40235888Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma.World J Gastrointest Oncol2025https://conductscience.org/library/papers/40235888PubMed
39936576Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.Am J Hematol2025https://conductscience.org/library/papers/39936576PubMed
39833882The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.BMC Pharmacol Toxicol2025https://conductscience.org/library/papers/39833882PubMed
38493006Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?Blood Rev2024https://conductscience.org/library/papers/38493006PubMed
37635400Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.Am J Hematol2023https://conductscience.org/library/papers/37635400PubMed
37434023Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.Invest New Drugs2023https://conductscience.org/library/papers/37434023PubMed
36975206Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.Cancer Rep (Hoboken)2023https://conductscience.org/library/papers/36975206PubMed
35680595[Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].Zhonghua Xue Ye Xue Za Zhi2022https://conductscience.org/library/papers/35680595PubMed
35150326Blue light induces ROS mediated apoptosis and degradation of AML1-ETO oncoprotein in Kasumi-1 cells.Med Oncol2022https://conductscience.org/library/papers/35150326PubMed
34638721Cancer Therapy Challenge: It Is Time to Look in the "St. Patrick's Well" of the Nature.Int J Mol Sci2021https://conductscience.org/library/papers/34638721PubMed
34320781Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?Haematologica2021https://conductscience.org/library/papers/34320781PubMed
30968179Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.Cancer Chemother Pharmacol2019https://conductscience.org/library/papers/30968179PubMed
30858954Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.Mediterr J Hematol Infect Dis2019https://conductscience.org/library/papers/30858954PubMed
30666113Idarubicin-loaded methoxy poly(ethylene glycol)-b-poly(l-lactide-co-glycolide) nanoparticles for enhancing cellular uptake and promoting antileukemia activity.Int J Nanomedicine2019https://conductscience.org/library/papers/30666113PubMed
29787320Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.Expert Rev Clin Pharmacol2018https://conductscience.org/library/papers/29787320PubMed
29779333[Clinical observation of standard IA regimen as induction chemotherapy in 242 patients with newly diagnosed acute myeloid leukemia].Zhonghua Xue Ye Xue Za Zhi2018https://conductscience.org/library/papers/29779333PubMed
29365393[Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients].Zhonghua Xue Ye Xue Za Zhi2017https://conductscience.org/library/papers/29365393PubMed
28154969What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?Curr Treat Options Oncol2017https://conductscience.org/library/papers/28154969PubMed

See all 73 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2015395

GET https://conductscience.org/api/papers/v1/2015395/cited_by?page=2